The study looks at adults with early polymyalgia rheumatica, an inflammatory condition that causes muscle pain and stiffness mainly in the shoulders and hips. The investigational medicine being tested is sarilumab, given as a solution for injection, and it is used together with a gradual reduction (taper) of the steroid prednisone. Participants may receive either the active medicine or a placebo that looks the same but does not contain the active drug.
The aim of the trial is to determine whether the combination of sarilumab and a 52‑week prednisone taper works better than prednisone taper alone in achieving lasting symptom control. Participants are randomly assigned to receive one of two dose levels of the study drug (150 mg or 200 mg) every two weeks, while all continue the steroid taper for one year, and they are followed for the same period to see how they respond.
Throughout the year, researchers check whether participants reach “remission,” meaning they have no significant pain or stiffness, and they record any side effects or laboratory changes. They also track how long remission lasts, whether symptoms return (a “flare”), and how the condition affects physical and mental well‑being using standard questionnaires. Safety is monitored continuously, and any serious problems are reported promptly.
Austria 
Belgium 
Czechia 
France 
Germany 
Greece 
Hungary 
Spain 
The Netherlands